495 related articles for article (PubMed ID: 31229934)
1. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
[TBL] [Abstract][Full Text] [Related]
2. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
[TBL] [Abstract][Full Text] [Related]
3. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
[TBL] [Abstract][Full Text] [Related]
4. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.
Gandhi RT; Bosch RJ; Aga E; Bedison MA; Bastow B; Schmitz JL; Siliciano JD; Siliciano RF; Eron JJ; Mellors JW;
Antivir Ther; 2013; 18(4):607-13. PubMed ID: 23411421
[TBL] [Abstract][Full Text] [Related]
5. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.
Ceccherini-Silberstein F; Cozzi Lepri A; Alteri C; Merlini E; Surdo M; Marchetti G; Capobianchi MR; De Luca A; Gianotti N; Viale P; Andreoni M; Antinori A; Perno CF; d'Arminio Monforte A;
J Antimicrob Chemother; 2018 Dec; 73(12):3460-3470. PubMed ID: 30247724
[TBL] [Abstract][Full Text] [Related]
6. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
7. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART.
Lombardi F; Belmonti S; Rapone L; Borghetti A; Ciccullo A; Gagliardini R; Baldin G; Montagnani F; Moschese D; Emiliozzi A; Rossetti B; De Luca A; Di Giambenedetto S
J Clin Virol; 2018 Jun; 103():57-62. PubMed ID: 29656086
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.
Besson GJ; Lalama CM; Bosch RJ; Gandhi RT; Bedison MA; Aga E; Riddler SA; McMahon DK; Hong F; Mellors JW
Clin Infect Dis; 2014 Nov; 59(9):1312-21. PubMed ID: 25073894
[TBL] [Abstract][Full Text] [Related]
10. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
11. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
[TBL] [Abstract][Full Text] [Related]
12. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
Lee SA; Bacchetti P; Chomont N; Fromentin R; Lewin SR; O'Doherty U; Palmer S; Richman DD; Siliciano JD; Yukl SA; Deeks SG; Burbelo PD
PLoS One; 2016; 11(8):e0160192. PubMed ID: 27483366
[TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
15. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
[TBL] [Abstract][Full Text] [Related]
16. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
17. Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts.
N'takpe JB; Gabillard D; Moh R; Gardiennet E; Emieme A; Badje A; Kouame GM; Toni TD; Karcher S; Carrou JL; Ménan H; Danel C; Eholie SP; Rouzioux C; Anglaret X
EBioMedicine; 2020 Jun; 56():102815. PubMed ID: 32512517
[TBL] [Abstract][Full Text] [Related]
18. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.
Mexas AM; Graf EH; Pace MJ; Yu JJ; Papasavvas E; Azzoni L; Busch MP; Di Mascio M; Foulkes AS; Migueles SA; Montaner LJ; O'Doherty U
AIDS; 2012 Nov; 26(18):2295-306. PubMed ID: 23014521
[TBL] [Abstract][Full Text] [Related]
19. Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
[TBL] [Abstract][Full Text] [Related]
20. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
